Evidence map›Paper›PMID 34121134›Full record

ArticleEJNMMI research2021

[

Jingjing Fu, Yan Xie, Tong Fu, Fan Qiu, Fei Yu, Wei Qu, Xiaochen Yao, Aiping Zhang, Zhenhua Yang, Guoqiang Shao and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Imaging the hallmarks of cancer.Nature reviews. Cancer · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Heterobivalent Dual-Target Peptide for Integrin-αPharmaceuticals (Basel, Switzerland) · 2024
    Article
  6. EGFR- and Integrin αInternational journal of molecular sciences · 2024
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Jingjing Fu *Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
Yan Xie *Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
Tong Fu *Department of Imaging, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Fan QiuDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
Fei YuDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
Wei QuDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
Xiaochen YaoDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
Aiping ZhangDepartment of Thoracic Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Zhenhua YangDepartment of Respiratory, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
Guoqiang ShaoDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
Qingle MengDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
Xiumin ShiDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
Yue HuangDepartment of Pathology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China. huangyuexxy@163.com.
Wei GuDepartment of Respiratory, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China. guw2001@126.com.
Feng WangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China. fengwangcn@hotmail.com.ORCID http://orcid.org/0000-0003-1089-3095
Nanjing Medical University · CN

Funding

Health Commission of Jiangsu Province H2019091Jiangsu Provincial Key Research and Development Special Fund BE2017612Nanjing Medical and Health International Joint Research and Development Project 201911042Nanjing Medical Foundation ZKX17027the National Natural Science Foundation of China 11805104the National Natural Science Foundation of China 82003532
6 · The paper itself

Abstract

backgroundEpidermal growth factor receptor tyrosine kinase inhibitors (TKIs) are beneficial in patients with lung cancer. We explored the clinical value of [

methodsA total of 185 patients with lung cancer and 25 patients with benign lung diseases were enrolled in this prospective study from January 2013 to December 2016. All patients underwent [

resultsThe lung cancer patients included 22 cases of small cell lung cancer (SCLC), 48 squamous cell carcinoma (LSC), 97 adenocarcinoma (LAC), and 18 other types of lung cancer. The sensitivity, specificity, and accuracy of [

conclusions[

Indexed as

[99mTc]Tc-Galacto-RGD2AngiogenesisBiological behaviourIntegrin αvβ3Lung cancer

Identifiers

PMID34121134
PMCPMC8200335
OpenAlexW3167457690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.